As of November 7, 2026, Vaxcyte, Inc. is a publicly traded company (Nasdaq: PCVX); its largest reported holder is Fidelity (FMR), with 14.4% on Schedule 13G/A of August 6, 2026, then JANUS HENDERSON GROUP Ltd. (12.1%). The largest insider holding is Grant Pickering, the chief executive and a director, with 563,117 shares (0.36% of shares outstanding), per Form 4 of September 9, 2026 (Schedule 13G/A, August 6, 2026).
Is this your company?
About to sign with, pay or invest in Vaxcyte, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vaxcyte, Inc. a real, registered company?
- Vaxcyte, Inc. files with the SEC under CIK 1649094 (its SEC filings).
- Its shares are listed under the ticker PCVX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Carlos, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under VAXCYTE INC in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Heath Lukatch (Form 8-K filed 2026-07-15). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-11-06).
Who are Vaxcyte, Inc.'s owners and officers?
Vaxcyte, Inc.: incorporated in Delaware; business address in San Carlos, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | T. Rowe Price Investment Management, Inc. | 9.6% |
| Schedule 13G/A, 2026-11-06 | T. Rowe Price Investment Management, Inc. | 11.6% |
| Schedule 13G/A, 2026-08-11 | Janus Henderson Group LTD. | 12.1% |
| Schedule 13G/A, 2026-08-07 | Janus Henderson Group LTD. | 0.1% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 14.4% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 11.5% |
| Schedule 13G/A, 2026-05-15 | Ra Capital Management, L.P. | 8.9% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 11.4% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.03% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | T. Rowe Price Investment Management, Inc. | 8.6% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 10.1% |
Questions about who owns Vaxcyte, Inc.
Who owns Vaxcyte, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Vaxcyte, Inc.: Fmr LLC (14.4%, Schedule 13G/A, filed 2026-08-06), Janus Henderson Group LTD. (12.1%, Schedule 13G/A, filed 2026-08-11), Janus Henderson Group PLC (11.5%, Schedule 13G/A, filed 2026-05-15), T. Rowe Price Investment Management, Inc. (9.6%, Schedule 13G/A, filed 2026-11-06) and Ra Capital Management, L.P. (8.9%, Schedule 13G/A, filed 2026-05-15); 1 more is listed above.
Who are the largest shareholders of Vaxcyte, Inc.?
By the share each holder's latest filing reports, the largest holders of Vaxcyte, Inc. on this page are Fmr LLC (14.4%), Janus Henderson Group LTD. (12.1%) and Janus Henderson Group PLC (11.5%).
When did Fmr LLC buy into Vaxcyte, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-05-06, reporting 11.4%; its latest, Schedule 13G/A filed 2026-08-06, reports 14.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vaxcyte, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vaxcyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vaxcyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-15 | Heath Lukatch | departed | 2026-07-16 | |
| Form 8-K, 2026-07-15 | John Markels | Director | appointed | 2026-07-16 |
| Form 8-K, 2026-06-23 | Jacks Lee | departed | 2026-06-17 | |
| Form 8-K, 2026-06-23 | Moncef Slaoui | Director | appointed |
Which insiders own Vaxcyte, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 563,117 shares (0.36% of shares outstanding), 429,902 held directly and 133,215 indirectly (Form 4, 2026-09-09).
- , the president and chief financial officer: 157,166 shares (0.10% of shares outstanding), 95,316 held directly and 61,850 indirectly (Form 4, 2026-09-09).
- , the chief operating officer and executive vice president: 145,435 shares (0.09% of shares outstanding) (Form 4, 2026-11-04).
- , the chief technical operations officer: 68,085 shares (0.04% of shares outstanding) (Form 4, 2026-09-09).
- , the chief medical officer: 52,632 shares (0.03% of shares outstanding) (Form 4, 2026-09-09).
Shares outstanding: 158,299,981 as of 2026-11-02, from the company's latest SEC cover page.
How much has Vaxcyte, Inc. raised?
No fundraising or offering filing from Vaxcyte, Inc. is on file with us.
Keep reading
More on Vaxcyte, Inc. and the records around it.
Vaxcyte, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vaxcyte